Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and spray… Read more
Caplin Point Laboratories Limited (CAPLIPOINT) - Total Liabilities
Latest total liabilities as of September 2025: ₹3.05 Billion INR
Based on the latest financial reports, Caplin Point Laboratories Limited (CAPLIPOINT) has total liabilities worth ₹3.05 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Caplin Point Laboratories Limited - Total Liabilities Trend (2007–2025)
This chart illustrates how Caplin Point Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Caplin Point Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Caplin Point Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Hifuture Electric
SHE:002168
|
China | CN¥867.90 Million |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
China | CN¥239.84 Million |
|
Tsukishima Holdings Co., Ltd.
F:QO3
|
Germany | €76.20 Billion |
|
Ag Growth International Inc
PINK:AGGZF
|
USA | $1.43 Billion |
|
Shaanxi Xinghua Chemistry Co Ltd
SHE:002109
|
China | CN¥5.83 Billion |
|
Sung Kwang Bend Co.Ltd
KQ:014620
|
Korea | ₩40.94 Billion |
|
Card Factory plc
PINK:CRFCF
|
USA | $300.10 Million |
|
Kunshan Asia Aroma Corp. Ltd.
SHE:301220
|
China | CN¥682.01 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Caplin Point Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.27 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caplin Point Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caplin Point Laboratories Limited (2007–2025)
The table below shows the annual total liabilities of Caplin Point Laboratories Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹3.22 Billion | -8.28% |
| 2024-03-31 | ₹3.51 Billion | +23.64% |
| 2023-03-31 | ₹2.84 Billion | +25.48% |
| 2022-03-31 | ₹2.26 Billion | +41.31% |
| 2021-03-31 | ₹1.60 Billion | -5.28% |
| 2020-03-31 | ₹1.69 Billion | +54.46% |
| 2019-03-31 | ₹1.10 Billion | -19.77% |
| 2018-03-31 | ₹1.37 Billion | +2.06% |
| 2017-03-31 | ₹1.34 Billion | +1.79% |
| 2016-03-31 | ₹1.31 Billion | -2.92% |
| 2015-03-31 | ₹1.35 Billion | +14.72% |
| 2014-03-31 | ₹1.18 Billion | +28.72% |
| 2013-03-31 | ₹916.67 Million | +24.74% |
| 2012-03-31 | ₹734.86 Million | +63.33% |
| 2011-03-31 | ₹449.92 Million | +28.29% |
| 2010-03-31 | ₹350.69 Million | -6.38% |
| 2009-03-31 | ₹374.59 Million | +9.54% |
| 2008-03-31 | ₹341.97 Million | +42.55% |
| 2007-03-31 | ₹239.89 Million | -- |